













1 EFRUZHU
MOLECULAR AND CELLULAR CANCER
CARCINOGENESIS THEORY AND LAWS
CONCLUSIVE PROOF PUBLICATIONS

2 EFRUZHU
OPPOSITION MULTIMODALITY
(MECHANISMS) ABSOLUTE ANY STAGE
ANTICANCER THERAPY DRUGHU
CONCLUSIVE PROOF PUBLICATIONS





EFRUZ ASILOGLU

APEX / SUPREMO DEGREE

PHILOSOPHER EFRUZHU PHRMP







EFRUZHU PROGNOSTIC MARKERS THEOREM AND ADVOCATES

© ®

NORTH CYPRUS TURKISH CYPRIOT

- 1.MOLECULAR GENETIC OF WILD NORMAL GENES HYPERMETHYLATION RATE
- 2.MOLECULAR PATHOLOGICAL GENES MUTATIONS / CHROMOSOMAL ABERRATIONS RATE
- 3.HISTOPATHOLOGICAL GRADES RATE
- 4.CLINICAL REGIONAL / DISTANT METASTASES RATE
- 5.BIOCHEMICAL AND MOLECULAR BIOLOGY MULTIPLE PARAMETERS EVALUATION RATE
- 6.IMMUNOHISTOCHEMISTRY PARAMETERS RATE
- 7.CLINICAL STAGE EXAMINATION OF DISEASE / PATIENTS VITAL PARAMETERS RATE
- 8.LOSS OF WILD ALLELES (LOSS OF HETEROZIGOSITY) RATE
- 9.CHROMOSOMAL EUPLOID / DIPLOID RATE



**EFRUZHU ANTICANCER /ANTINEOPLASTIC
DRUG RESISTANCE
THEOREM AND ADVOCATES**

© ®

NORTH CYPRUS TURKISH CYPRIOT

- 1.MOLECULAR ENERGY METABOLISM RATE
- 2.MUTATIONS RECEPTORS - CHANNELOPATHY RATE
- 3.CLINICAL STAGE OF DISEASE / PATIENTS
- 4.WILD NORMAL DNA GENES HYPERMETHYLATION / HYPOMETHYLATION RATE
- 5.LOSS OF WILD NORMAL ALLELES RATE
- 6.MOLECULAR OXIDANT / ANTIOXIDANT RATE

7. PROINFLAMMATORY / INFLAMMATION GROWTH FACTORS , CYTOKINES RATE
8. SUCCESSFUL MOLECULAR AND CELLULAR PHAGOSITOSIS , APOPTOSIS , MATURATION ,
MULTIPLE OPPOSITES BALANCED RATE
9. SOMATIC AND PSYCHOLOGICAL OPPOSITES BALANCED RATE



**UNIQUE “ MGSMM ” OF ALL CANCERS ONE
CLASSIFICATION © ®
EFRUZHU NORTH CYPRUS
(TURKISH CYPRIOT)
CLINICAL MEDICAL ONCOLOGY STAGING
SYSTEM**

MOLECULAR GENETIC HISTOPATHOLOGY STAGE METASTASES

M1	G1	S1	M1
M2	G2	S2	
M3	G3	S3	M2
M4	G4	S4	

M1:% 0 – 25 TOTAL WILD DNA MUTATIONS PROPORTION
M2:% 26 – 50 TOTAL WILD DNA MUTATIONS PROPORTION
M3:% 51 – 75 TOTAL WILD DNA MUTATIONS PROPORTION
M4:% 76 – 100 TOTAL WILD DNA MUTATIONS PROPORTION

G1:GRADE 1 WELL DIFFERENTIATED
G2:GRADE 2 MODERATELY DIFFERENTIATED
G3:GRADE 3 POORLY DIFFERENTIATED
G4:GRADE 4 UNDIFFERENTIATED

S1:CLINICAL STAGE DISEASE/PATIENTS
S2:CLINICAL STAGE DISEASE/PATIENTS
S3:CLINICAL STAGE DISEASE/PATIENTS
S4:CLINICAL STAGE DISEASE/PATIENTS

M1:LOCOREGIONAL-NEARBY (LOCAL REGIONAL) LYMPH NODES METASTASES

M2:DISTANT METASTASES

STAGING OF CLINICAL MEDICAL ONCOLOGY FIGURES:

1)MOLECULAR FIGURE 2)PATHOLOGIC FIGURE 3)CLINICAL FIGURE
4)CLINICAL TRIAL FIGURE



EFRUZHU METASTASIS THEOREM AND ADVOCATES

© ®

NORTH CYPRUS TURKISH CYPRIOT

1. INADEQUATE NUTRITION
2. INADEQUATE OXYGENATION
3. HIGHER MITOTIC ACTIVITY
4. HIGHER MUTATIONAL MOLECULAR AND CELLULAR METABOLIC ACTIVITY
5. HIGHER WASTE PRODUCTS
6. HIGHER OXIDATIVE METABOLIC STRESS
7. LOWER ANTIOXIDANT QUANTITIES
8. LOWER AEROBIC GLYCOLYSIS / TCA (KREBS CYCLE)

9.HIGHER MUTATIONAL GENES DESTRUCTIVE / ANGIOGENIC / ANTISTABILIZATOR FACTORS ACTIVITY

EFRUZHU ONCOMEDICUS LAWS

1. ALL OF THE CANCER TYPES NEED TO NORMAL AND MUTATIONS DYNAMICS OPPOSITION BALANCED WITH SHARING CODOMINANT (EQUALLY DOMINANT) FUNCTIONALITY.
2. FEEDBACK MECHANISMS HAD BEEN FORMATED BETWEEN NORMAL IDENTITY AND MUTATIONS IDENTITY .
3. MAIN ESSENTIAL THERAPEUTIC DRUGS :
NF-Kb + ANTIINFLAMMATION FOR MUTATIONS IDENTITY. HDAC + DNMT + GLYCOSAMINOGLYCAN + ELECTROLYTE + SIGNALING + HOLY DIVINEHU FOR NORMAL IDENTITY .
4. THERAPEUTIC STYLE HAD BEEN ESTABLISHED CONVENTIONAL AND UNCONVENTIONAL (HERBAL-NATURAL) DRUGS
5. TRETMENT METHOD IS TRIPLE KEY METHOD (TRIGEMINUS CLAVIS MODUS)
MATURATION,APOPTOSIS,PHAGOSITOSIS AT THE SAME TIME .

6. HOLY DIVINEHU SPIRITUAL ACTIVATION FOR
SPIRITUAL AND MATERIAL BODIES OPPOSITION
BALANCED .

EFRUZHU ONCOMEDICUS FORMULAE

NF-kB INHIBITOR : M1

ANTIINFLAMMATION : M2

HDAC INHIBITOR : N1

DNMT INHIBITOR : N2

GLYCOSAMINOGLYCAN : N3

ELECTROLYTE : N4

SIGNALING : N5

HOLY DIVINEHU : N6

M : MUTATIONS DYNAMICS DRUGS

N : NORMAL DYNAMICS DRUGS

ABSOLUTE ANY STAGE ONCOTHERAPY :OT

1.)

$$\text{OT} = \frac{\text{N1+N2+N3+N4+N5+N6}}{\text{M1+M2}}$$

2.)

$$\text{OT: N1+N2+N3+N4+N5+N6} - (\text{M1+M2})$$

3.)

$$\text{OT: } N_1 \times N_2 \times N_3 \times N_4 \times N_5 \times N_6 - (M_1 \times M_2)$$

4.)

$$\text{OT: } N_1 + N_2 + N_3 + N_4 + N_5 + N_6 = M_1 + M_2 = 0$$

5.)

$$\text{OT: } N_1 \times N_2 \times N_3 \times N_4 \times N_5 \times N_6 = M_1 \times M_2 = 0$$





APEX DEGREE

TURKISH CYPRIOT PHILOSOPHER EFRUZHU

PHRMP

PROFESSIONAL

CONSULTANT MEDICAL ONCOLOGY PCMO

TURKISH REPUBLIC OF NORTHERN CYPRUS
NORTH CYPRUS

1.EFRUZHU ANTINEOPLASTIC DOSAGE REGIMENS
THEORYEM

<http://essafihucancertrea.wixsite.com/nf-kb-drughu>

3.EFRUZHU CANCER CARCINOGENESIS
THEORY AND LAWS

ORIGINAL

**PHILOSOPHER EFRUZHU ABSOLUTE ANY STAGE CANCER
DISEASE THERAPY**

« ANTICANCER MEDICINE EFRUZHU NORTH CYPRUS ® »

**ANTICANCER MEDICINE APPLICATION
PROTOCOL AND PROCESSING**

CHEMOHERBAL TREATMENT METHOD ©

- 1.NF-kB INHIBITOR (PROTEOSOME INHIBITOR)
- 2.DNMT INHIBITOR AND HDAC INHIBITOR
- 3.INFLAMMATION SUPPRESSION
- 4.GLYCOSAMINOGLYCANS CORRECTION
- 5.ELECTROLYTE AND WATER REBALANCED
- 6.HIGH ENERGY PHOSPHATE COMPOUND AND ANTIOXIDANT RECHARGED
- 7.NORMAL SELF SIGNALING PATHWAYS REACTIVATION
- 8.CHEMICAL AND HERBAL MEDICINE OPPOSITION NEW REBALANCED
- 9.OPPOSITION BALANCED OF MATERIAL BODY AND
ORIGINAL HOLY DIVINEHU SPIRITUAL BODY
DYNAMICS ACTIVATION .

ALIMHU/HABIRHU PHILOSOPHER EFRUZHU PHRMP
NORTH CYPRUS TURKISH CYPRIOT

www.youtube.com/efrzhucancertheory



**EFRUZHU CYPRIUS TURCICA
(CYPRUM TURCA)**

**“TRIGEMINUS CLAVIS MODUS”
(TRIPLE KEY METHOD)**

1.MATURATION

2.APOPTOSIS

3.PHAGOSITOSIS

(AT THE SAME TIME)

**ABSOLUTE ANY STAGE ONCOTHE
RAPY**



EFRUZHU CYPRIUS TURCICA (CYPRUM TURCA)

"TRIGEMINUS CLAVIS MODUS"

(TRIPLE KEY METHOD)

**1.MATURATION 2.APOPTOSIS 3.PHAGOSITOSIS
(AT THE SAME TIME)**

ABSOLUTE ANY STAGE ONCOTHERAPY

FORMULAE® ©

ONCOTHERAPY : OT

HDAC +DNMT INHIBITOR ACTIVITY

$$(1.) OT = \frac{\text{HDAC + DNMT}}{\text{INHIBITOR ACTIVITY}}$$

NF-KB

INHIBITOR ACTIVITY

$$(2.) OT = \text{HDAC + DNMT} - \text{NF-KB}$$

HDAC X DNMT INHIBITOR ACTIVITY

$$(3.) OT = \frac{\text{HDAC} \times \text{DNMT}}{\text{INHIBITOR ACTIVITY}}$$

NF-KB

INHIBITOR ACTIVITY





EFRUZHU RECURRENCE/RELAPSE THEOREM AND ADVOCATES

© ®

NORTH CYPRUS TURKISH CYPRIOT

- 1.HIGHER NF-KB ACTIVITY
- 2.HYPERMETHYLATION OF NORMAL WILD DNA GENES
- 3.CHRONIC INFLAMMATION
- 4.HIGHER GROWTH FACTORS , CYTOKINES , PROINFLAMMATIORIAL STIMULATION
- 5.INADEQUATE ENERGY
- 6.NORMAL WILD DNA HISTONES MODIFICATIONS SUPPRESSION
- 7.LOSS OF HETEROZYGOSITY

**8.INCREASING MUTATIONS AND DECREASING WILD NORMAL GENES CELLULAR
GOVERNING ACTIVITY
9.STRONG / HIGHER OXIDANT ACTIVITY**



EFRUZHU SURVIVAL OUTCOMES THEOREM AND ADVOCATES

© ®

NORTH CYPRUS TURKISH CYPRIOT

- 1.NEOPLASTIC TRANSFORMATIONS OF BENIGN - MALIGN RATE**
- 2.WILD NORMAL DNA GENES SUCCESSFUL EXPRESSION RATE**
- 3.CLINICAL DISEASE / PATIENTS RECURRENCE – RELAPS REGIONAL / DISTANT RATE**
- 4.MOLECULAR GENETIC STABILITY – INSTABILITY RATE**
- 5.ORGANS AND TISSUES PATHOLOGICAL ABNORMALITY RATE**
- 6.WILD ALLELIC LOSS AND MUTATIONS, CHROMOSOMAL ABERRATIONS RATE**
- 7.REGIONAL / DISTANT METASTASES RATE**

8.ANTICANCER – ANTINEOPLASTIC DRUG TREATMENT –THERAPY REMISSION RATE
9.PROGNOSTIC SIGNIFICANCE INDICATOR / MARKER / VALUES RATE

EFRUZHU NORTH CYPRUS
(TURKISH CYPRIOT) ®
MOLECULAR AND CELLULAR & CLINICAL
MEDICAL ONCOLOGY PRINCIPLES/FORMULAE

SURVIVAL , METASTASIS , RECURRENSIS ,
PROGNOSIS

$$X = \frac{\text{DIRECTLY PROPORTIONAL}}{\text{INVERSELY PROPORTIONAL}}$$

$$\text{ENERGY} = \frac{\text{HYPOMETHYLATION GENES EXPRESSION}}{\text{HYPERMETHYLATION GENES SILENCED}}$$

$$\text{ENERGY} = \frac{\text{MUTATIONS GENES EXPRESSION}}{\text{WILD ALLELES LOSS (LOSS OF HETEROZYGOSITY)}}$$

$$\text{APOPTOSIS (PROGRAMMED CELL DEATH)} = \frac{\text{ENERGY DEGREE}}{\text{MUTATIONS GENES DEGREE}}$$

$$\begin{aligned} &\text{ANTINEOPLASTIC – ANTICANCER DRUG RESISTANCE} \\ &\quad \text{MUTATIONS GENES RECEPTORS RATE} \\ &= \frac{\quad}{\text{ENERGY RATE}} \end{aligned}$$

$$\text{MALIGNITY DEGREE} = \frac{\text{MUTATIONS DEGREE}}{\text{ENERGY DEGREE}}$$

CANCER THERAPY SURVIVAL DEGREE = APOPTOSIS
+ PHAGOSITOSIS + MULTIPLE OPPOSITES BALANCED + MATURATION
AT THE SAME TIME

$$\text{MALIGN CANCER CELL} = \frac{\text{ANAEROBIC GLYCOLYSIS ENERGY RATE}}{\text{AEROBIC} + \text{TCA CYCLE ENERGY RATE}}$$

$$\text{BENIGN NEOPLASTIC CELL} = \frac{\text{AEROBIC GLYCOLYSIS} + \text{TCA CYCLE ENERGY RATE}}{\text{ANAEROBIC GLYCOLYSIS ENERGY RATE}}$$

RECURRENS RELAPS FORMULAE =
EFRUZHU MOLECULAR AND CELLULAR CARCINOGENESIS LAWS
1. MUTATIONS GROUP IDENTITY 2. INADEQUATE ENERGY 3. CHRONIC
INFLAMMATION 4. NORMAL WILD DNA SUPPRESSION + GROWTH
FACTORS + CYTOKINES + NF-Kb + HYPOOXYGENATION + INADEQUATE
NUTRITION.

$$\text{SURVIVAL RATE/OVERCOME} = \frac{\text{CHROMOSOMAL ABERRATIONS DEGREE}}{\text{WILD CHROMOSOMAL DEGREE}}$$

OR

$$\text{SURVIVAL RATE/DEGREE} = \frac{\text{MUTATIONS GENES DEGREE}}{\text{WILD } \frac{\text{GENES}}{\text{ALLELES}} \text{ DEGREE}}$$

$$APOPTOSIS = \frac{\frac{ENERGY}{WILD GENES ALLELES} DEGREE}{NF - kB DEGREE}$$

$$SURVIVAL RATE = \frac{DIPLOID RATE}{ANEUPLOID RATE}$$

$$MALIGNITY DEGREE = \frac{ANEUPLOID DEGREE}{DIPLOID DEGREE}$$

LOSS OF HETEROZYGOSITY SURVIVAL RATE DECREASING, NO
LOSS WITHOUT HETEROZYGOSITY SURVIVAL RATE INCREASING

$$SURVIVAL RATE = \frac{EXISTANCE PHYSIOLOGIC BALANCED RATE}{LOST OF HOMEOSTATIC BALANCED RATE}$$

OR

$$SURVIVAL RATE = \frac{MOLECULAR GENETIC STABILITY RATE}{PATHOLOGICAL ABNORMALITY RATE}$$

HIGHER OF RECURRENCE PARALLEL OF METASTASIS, HIGHER
RISK OF METASTASIS PARALLEL OF HIGHER MITOTIC COUNT /
ACTIVITY ALSO RECURRENCE, CONTRARY LOW MITOTIC COUNT
/ACTIVITY WITHOUT /NO PARALLEL THE POSSIBILITY OF
METASTASIS.

WILD ALLELIC LOSS AND MUTATIONS EQUAL WILD DNA
GENETIC INSTABILITY , ABERRATIONS , GENETIC ABNORMALITY.

SURVIVAL OUTCOMES:

1.MALIGNITY DEGREE 2.MUTATIONS DEGREE 3.CHROMOSOMAL ABNORMALITY (ANEUPLOIDY/ABERRATIONS DEGREE) 4.ENERGY MAIN WAYS (AEROBIC/UNAEROBIC GLYCOLYSIS AND TCA/KREBS CYCLE DEGREE 5.HOMEOSTATIC BALANCED IMBALANCED OF ALL VITAL PARAMETERS DEGREE 6.NODAL INVOLMENT DEGREE 7.METASTASES 8.RECURRENCES 9.SPIRITUAL COGNITIVE DYNAMICS DISTURBANCES RATE

HOMEOSTATIC BALANCED DEPENDENCE OF MALIGNITY DEGREE THAT PARALLEL OF ACIDS DEGREE

METASTASIS DEPENDENCE:

OXYGEN RATE

NUTRITION RATE

HIGHER MITOTIC ACTIVITY RATE

WASTE PRODUCTS RATE

STABILITY-INSTABILITY CONDITIONS/DYNAMICS/FACTORS RATE



EFRUZHU PROGNOSIS THEOREM AND ADVOCATES

© ®

NORTH CYPRUS TURKISH CYPRIOT

- 1.CHROMOSOMAL ABERRATIONS RATE
- 2.GENES MUTATIONS RATE
- 3.MOLECULAR / CLINICAL PATHOLOGICAL CONDITIONS RATE
- 4.ANTINEOPLASTIC – ANTICANCER DRUG RESISTANCE RATE
- 5.ORGAN SYSTEMS AND TISSUES HOMEOSTATIC PHYSIOLOGIC BALANCED RATE
- 6.VITAL PARAMETERS REFERENCE VALUES OPTIMAL RATE
- 7.SOMATIC BODY AND SPIRITUAL - PSYCHOLOGICAL BODY NUTRITIONAL RATE
- 8.METABOLIC / MOLECULAR GENETIC TOXICATION RATE
- 9.CLINICAL STAGE OF DISEASE / PATIENTS RATE

